Glimepiride Zentiva (Glimepiride)

Glimepiride Zentiva is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient. It is typically prescribed as part of a comprehensive treatment plan that may include other oral agents or insulin.

• Improves glycemic control in adults with type 2 diabetes.
• Used as monotherapy or in combination with other antidiabetic drugs.
• Helps reduce fasting and post‑prandial blood glucose levels.
• May be considered when sulfonylurea therapy is appropriate.
• Supports long‑term management of diabetes alongside lifestyle modifications.

Glimepiride Zentiva may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require medical attention.

Common

• Low blood sugar (hypoglycemia).
• Nausea or upset stomach.
• Headache.
• Dizziness.
• Weight gain.
• Skin rash or itching.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as swelling of the face, lips, or throat.
• Liver function abnormalities.
• Blood disorders like leukopenia or thrombocytopenia.
• Pancreatitis symptoms (abdominal pain, vomiting).

Before starting Glimepiride Zentiva, certain health considerations should be reviewed to minimize risks and ensure safe use.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Use cautiously in elderly patients who may be more susceptible to low blood sugar.
• Evaluate for a history of allergic reactions to sulfonylureas.
• Discuss pregnancy or breastfeeding plans with a healthcare provider.
• Adjust dose if the patient is taking other medications that affect glucose levels.
• Advise patients to carry identification indicating they are on a sulfonylurea.

Glimepiride Zentiva can interact with several other medicines, altering its effectiveness or increasing the risk of side effects.

Avoid

• Other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride levels.
• MAO‑B inhibitors, which may enhance hypoglycemic effects.

Use with caution

• Beta‑blockers, as they may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose.
• Corticosteroids, which may reduce the drug’s glucose‑lowering effect.
• Antifungal agents like itraconazole, requiring closer glucose monitoring.
• NSAIDs, which can affect renal function and glucose control.